Balance Sheet
Cash Flow Statement
AcquisitionsAmortization of Deferred ChargesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Firefly Neuroscience (AIFF) Change in Account Payables (2017 - 2025)

Firefly Neuroscience has reported Change in Account Payables over the past 9 years, most recently at $2000.0 for Q4 2025.

  • Quarterly results put Change in Account Payables at $2000.0 for Q4 2025, down 99.35% from a year ago — trailing twelve months through Dec 2025 was -$630000.0 (down 171.35% YoY), and the annual figure for FY2025 was -$630000.0, down 171.35%.
  • Change in Account Payables for Q4 2025 was $2000.0 at Firefly Neuroscience, up from -$157000.0 in the prior quarter.
  • Over the last five years, Change in Account Payables for AIFF hit a ceiling of $1.2 million in Q2 2022 and a floor of -$1.3 million in Q3 2022.
  • Median Change in Account Payables over the past 5 years was $12500.0 (2023), compared with a mean of $4974.6.
  • Biggest five-year swings in Change in Account Payables: crashed 988.46% in 2022 and later soared 1243.48% in 2024.
  • Firefly Neuroscience's Change in Account Payables stood at -$620205.0 in 2021, then soared by 155.82% to $346229.0 in 2022, then crashed by 93.36% to $23000.0 in 2023, then soared by 1243.48% to $309000.0 in 2024, then plummeted by 99.35% to $2000.0 in 2025.
  • The last three reported values for Change in Account Payables were $2000.0 (Q4 2025), -$157000.0 (Q3 2025), and -$271000.0 (Q2 2025) per Business Quant data.